The code of conduct was issued, and the supervision of medical representatives was further upgraded.
Recently, the Liaoning Provincial Food and Drug Administration organized the Liaoning Pharmaceutical Industry Association, the Liaoning Pharmaceutical Association, and the Liaoning Biotechnology Association to jointly formulate the "Code of Conduct for Medical Representatives in the Pharmaceutical Industry in Liaoning Province", clarifying the "nine prohibitions" code of conduct for the promotion of drugs by medical representatives, and on January 18, 2024, through a combination of online and offline, the Liaoning Provincial Pharmaceutical Industry Medical Representative Code of Conduct Conference was organized. 
According to the official account of the Liaoning Pharmaceutical Industry Association, more than 400 people, including the heads of pharmaceutical enterprises, marketing authorization holders and medical representatives in Liaoning Province, attended the meeting, and all the on-site participating companies submitted the "Provincial Pharmaceutical Marketing Authorization Holders and Medical Representatives to Sign the Letter of Commitment" to the conference. It was mentioned at the press conference that the Liaoning Provincial Food and Drug Administration will continue to strengthen the management of the filing of medical representatives, urge the holder to upload and maintain the filing information of medical representatives in a timely and accurate manner, carry out compliance inspections on the business conduct of medical representatives in accordance with the law, standardize the order of drug production and operation, and ensure the safety of drug use by the people. At present, the specific content of the Code of Conduct for Medical Representatives in the Pharmaceutical Industry of Liaoning Province has not been publicly released. The Administrative Measures for the Filing of Medical Representatives (Trial) formulated by the State Food and Drug Administration clarifies the prohibited behaviors of medical representatives. The details are as follows:
In the past, medical representatives were regarded as professional talents and were highly respected, but with the rapid development of the market, the proportion of sales attributes has become higher, breeding some industry chaos of gray benefit delivery. In recent years, many places have issued relevant documents to clearly strengthen the management of medical representatives. 
With the refinement of management, a number of medical institutions have also formulated more specific requirements for the admission of medical representatives. The First Affiliated Hospital of Anhui Medical University issued the "Notice on the Implementation of the Regulations on the Management of In-hospital Reception of Medical Representatives", which clearly and strictly implements the management system of "three determinations" and "three haves", that is, "regular and fixed-point appointments" and "appointments, processes and records". Zhuhai Hospital, Guangdong Provincial Hospital of Traditional Chinese Medicine, issued the "Regulations on the Management of Medical Representatives' Visits", which clearly requires that medical representatives must make an appointment for registration five working days in advance, and only visit the hospital on the same day after the review is passed. Under the multi-layer supervision, the survival mode of medical representatives in the past has ushered in severe challenges, and this trend will become more and more obvious with the development of compliance in the pharmaceutical industry. In 2024, the high-pressure situation of pharmaceutical anti-corruption will not decrease, and medical representatives, as a key role in the circulation of drugs and devices, will naturally be one of the key groups subject to supervision. Recently, the inspection of the fifth ** hospital in the country was officially launched, and "whether to strengthen the supervision of violating the "nine standards" and honest practice behaviors such as accepting commercial commissions, participating in fraud and insurance fraud, implementing excessive diagnosis and treatment, accepting donations in violation of regulations, leaking patient privacy, referring patients for profit, undermining the fairness of medical treatment, accepting "red envelopes" from patients, and accepting corporate kickbacks" as the focus of the inspection. Through comparison, it can be seen that the above-mentioned articles are all prohibitions on the work of medical representatives expressly stipulated in the Administrative Measures for the Filing of Medical Representatives (for Trial Implementation). In August last year, the official website of the People's Procuratorate of Songzi City, Hubei Province issued a notice that the Songzi City Procuratorate imposed a penalty on one person in accordance with the lawFraudulent health insurance**The suspect was prosecuted on suspicion of fraud. The article pointed out that the person was a sales companyMedical Representatives, responsible for the sale of a targeted drug for lung cancer, which requires a positive genetic test report to enjoy the national medical insurance reimbursement policy. In addition to hospital inspections, Qinghai, Jiangxi, Guangdong and other places have also carried out actions to collect clues on commercial bribery in the pharmaceutical field, supplementing regulatory coverage through the mode of "reporting". Pharmaceutical enterprises, medical and health institutions, and their associated distributors, pharmaceutical promotion companies, medical representatives, and relevant staff are all within the scope of the solicitation.
Cyberblue instrument drawing.
With the gradual improvement of supervision, the chain of accountability for violations is being strictly investigated, and the era of enterprises "dumping" medical representatives to evade punishment is coming to an end. For example, the Chongzuo Municipal People's Hospital in Guangxi Province proposed that if the representative is found to have violated the rules of the system, the medical representative and the enterprise will be included in the hospital blacklist and prohibited from business activities in the hospital for five years.
Based on the full-coverage system governance, coupled with the impact of various big data tools, the living space of traditional medical representatives is being significantly squeezed. According to statistics, the United States has a population of 300 million, and the number of medical representatives is about 78,000. At this rate**, there may be a large number of Chinese medical representatives who will be eliminated in the future competition. Looking back, the development of almost all industries has continued the path from savage growth to rational return. When the market tends to be rational and stable, the requirements for practitioners will gradually increase. The behavior of traditional medicine that no longer adapts to the current era may gradually die, but the brave who choose to keep pace with the times are expected to usher in new opportunities. In the 2015 edition of the Occupational Classification Dictionary of the People's Republic of China, the occupational content requirements for medical representatives are "on behalf of drug manufacturers, engaged in drug information transmission, communication and feedback."Professionals”。After this reshuffle, the medical representatives who will eventually remain may return to the status of "academic experts" and gain more respect in the era of compliance management. - end -
* |Written by Cyberblue Instruments |Alyosha.
Statement: The manuscripts marked in this WeChat are **, only for sharing, and do not represent the position of the platform, if it involves copyright and other issues, please contact us as soon as possible, we will correct it as soon as possible, thank you.